Report Overview

The EU Asthma and COPD Drugs market is expected to grow from USD XX billion in 2019 to USD XX billion in 2028 at a compound annual growth rate (CAGR) of XX%

Asthma is a chronic respiratory disease blocking the airways of the lung because of inflammation, mucus production, tightening of muscles. Chronic Obstructive Pulmonary Disease(COPD) is caused by an obstruction in the airways causing difficulty in breathing, with the primary cause as tobacco smoking. Increasing member of smokers is also expected to aid in the growth of the market. 600,000 people die every year in the EU from respiratory disease. Over half of these deaths are due to lung cancer or COPD and are linked to smoking. In the EU, the greatest burden is from COPD and
asthma which is approximately over 200 billion euros. Combination Therapies held a dominant position in the EU Asthma and COPD market in 2019, accounting for Bronchodilators and Anti-Inflammatories, respectively



Market Growth Drivers

The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of this market. The market is driven by the growing patient of COPD and asthmatic population. A growing aging population coupled with increasing automotive and industrial exhaust gases. The growth of the EU market is driven by the increasing COPD and asthma prevalence and rising number of smokers. Asthma and COPD drug market is likely to register a significant boost over the analysis period, which would create potential opportunities for new market players to grow. An increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness are the major factors that will fuel the growth of the Asthma and COPD Drug. However, stringent government regulatory requirements for the approval of asthma and COPD drugs, the asthma and COPD drugs showing side effects, patent expiry of the drugs restrict the market growth